Because HDAC4 positively regulates HIF-1α stability and transcriptional activity and negatively regulates transcriptional activity of MEF262–64, pharmacologic inhibition of HDAC4 with HDACs class IIa selective inhibitors represents a promising approach to therapy of GBM and may have synergistic effects when combined with radiotherapy. Here, HIF1A is linked to glioblastoma.